Exploiting the DCAF16–SPIN4 interaction to identify DCAF16 ligands for PROTAC development

Traditional small molecule drugs often target protein activity directly, but challenges arise when proteins lack suitable functional sites. An alternative approach is targeted protein degradation (TPD), which directs proteins to cellular machinery for proteolytic degradation. Recent studies have identified additional E3 ligases suitable for TPD, expanding the potential of this approach. Among these, DCAF16 has shown promise in facilitating protein degradation through both PROTAC and molecular glue mechanisms. In this study, we developed a homogeneous time resolved fluorescence (HTRF) assay to discover new DCAF16 binders. Using an in-house electrophile library, we identified two diastereomeric compounds, with one engaging DCAF16 at cysteines C177-179 and another reducing its expression. We demonstrated that the compound covalently engaging DCAF16 can be transformed into a PROTAC capable of degrading FKBP12.

Authors

Institutions

Publication Details

Journal
RSC Medicinal Chemistry
Published
2024-12-06
DOI
https://doi.org/10.1039/d4md00681j
Citations
3
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploiting the DCAF16–SPIN4 interaction to identify DCAF16 ligands for PROTAC development

Fiona Y. Wang, Sara F. Dunne, Benjamin F. Cravatt, Miguel Campos et al.
3 citations
RSC Medicinal Chemistry
Protein Degradation and Inhibitors
0.70
article

Exploiting the DCAF16–SPIN4 interaction to identify DCAF16 ligands for PROTAC development

Fiona Y. Wang, Sara F. Dunne, Benjamin F. Cravatt, Miguel Campos, Xiao‐Kang Jin, Isabella A. Riha, Xiaoyu Zhang, Chenlu Zhang
article en
3 citations

Abstract

Traditional small molecule drugs often target protein activity directly, but challenges arise when proteins lack suitable functional sites. An alternative approach is targeted protein degradation (TPD), which directs proteins to cellular machinery for proteolytic degradation. Recent studies have identified additional E3 ligases suitable for TPD, expanding the potential of this approach. Among these, DCAF16 has shown promise in facilitating protein degradation through both PROTAC and molecular glue mechanisms. In this study, we developed a homogeneous time resolved fluorescence (HTRF) assay to discover new DCAF16 binders. Using an in-house electrophile library, we identified two diastereomeric compounds, with one engaging DCAF16 at cysteines C177-179 and another reducing its expression. We demonstrated that the compound covalently engaging DCAF16 can be transformed into a PROTAC capable of degrading FKBP12.

RSC Medicinal ChemistryVol. 16(2)
Northwestern University (US), Scripps Research Institute (US), High Throughput Biology (United States) (US)
National Science Foundation, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences
Openalex Percentile: Top 28%
Protein Degradation and Inhibitors
0.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.